Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:254.

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib

Bin Zhao _ and Hong Zhao

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:93813-93824. https://doi.org/10.18632/oncotarget.21217

Metrics: PDF 1733 views  |   HTML 1919 views  |   ?  


Bin Zhao1 and Hong Zhao1,2

1Center for Scientific Research, The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, 325027, China

2Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, 150081, China

Correspondence to:

Bin Zhao, email: [email protected]

Hong Zhao, email: [email protected]

Keywords: regorafenib, hematologic toxicity, cancer, adverse event

Received: June 30, 2017     Accepted: August 27, 2017     Published: September 23, 2017


Regorafenib, an oral vascular endothelial growth factor receptor tyrosine-kinase inhibitor, has been approved for the treatment of several malignancies. As a non-traditional cytotoxic chemotherapeutic agent, regorafenib is often associated with hematologic toxicities. Here we searched PubMed and Embase up to June 2017 for relevant clinical trials. Eligible studies include trials in which subjects treated with 160 mg of regorafenib daily during the first 21 days of each 28-day cycle, and adequate safety data profile reporting thrombocytopenia, anemia, neutropenia and leucopenia. Statistical analyses were conducted to calculate the overall incidences, relative risks (RRs) and their 95% confidence intervals (CIs). A total of 2,341 subjects from 16 trials were included in the present studies. The incidences of regorafenib associated all-grade and high-grade hematologic toxicities were: thrombocytopenia, 22% and 3%; anemia, 20% and 3%; neutropenia, 10% and 2%, and leucopenia, 13% and 2%, respectively. Regorafenib-treated subjects had a significant increased risk of all-grade (RR=6.35; 95% CI, 3.19-12.64) and high-grade (RR=6.27; 95% CI, 1.69-23.26) thrombocytopenia, all-grade (RR=2.76; 95% CI, 1.63-4.68) and high-grade (RR=5.38; 95% CI, 1.60-18.06) anemia. Our results suggested that regorafenib therapy was associated with significantly increased risks of hematological toxicities, and hematologic monitoring at regular intervals should be advised to clinician.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21217